Pulse Biosciences (NASDAQ:PLSE) Trading Down 7.8% - Time to Sell?

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s share price traded down 7.8% during trading on Wednesday . The company traded as low as $20.46 and last traded at $20.18. 125,583 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 149,235 shares. The stock had previously closed at $21.89.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Thursday, January 2nd.

Pulse Biosciences Price Performance

The firm has a 50-day moving average price of $19.33 and a two-hundred day moving average price of $18.31.

Insider Buying and Selling at Pulse Biosciences

In other news, Director Robert W. Duggan acquired 55,256 shares of the stock in a transaction dated Friday, December 13th. The shares were acquired at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the transaction, the director now owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now owns 63,172 shares of the company's stock, valued at $1,100,456.24. The trade was a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 71.50% of the company's stock.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Pulse Biosciences during the 3rd quarter worth about $588,000. Charles Schwab Investment Management Inc. lifted its stake in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock worth $2,598,000 after purchasing an additional 97,565 shares during the period. State Street Corp boosted its holdings in Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company's stock valued at $8,092,000 after purchasing an additional 69,696 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock valued at $8,020,000 after purchasing an additional 33,200 shares in the last quarter. Finally, Franklin Resources Inc. bought a new stake in shares of Pulse Biosciences in the 3rd quarter valued at approximately $378,000. Institutional investors own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.